Champions Biotechnology, Inc. Acquires Rights to Cancer Drug Candidates
15 February 2007 - 7:17AM
PR Newswire (US)
ARLINGTON, Va., Feb. 14 /PRNewswire-FirstCall/ -- Champions
Biotechnology, Inc. (OTC:CSBR) (BULLETIN BOARD: CSBR) , a
development stage biotechnology company, announced today the
acquisition of patent rights encompassing two Benzoylphenylurea
(BPU) sulfur analog compounds that have shown promising potent
activity against prostate and pancreatic cancer cell lines (Journal
of Medicinal Chemistry, 2006, Vol. 49, No.7, 2357-2360). The
acquired rights include pending U.S. Patent Application no.
11/673,519 and corresponding international patent application
(PCT/US2006/014449) filed under the Patent Cooperation Treaty
(PCT), both entitled Design and Synthesis of Novel Tubulin
Polymerization Inhibitors: Benzoylphenylurea (BPU) Sulfur Analogs.
These antimitotic inhibitors target MAPT (Microtubule-Associated
Protein Tau) deficient tumors, a common feature of solid tumors,
and have performed better than Docetaxel (Taxotere) in the
difficult to treat direct patient xenograft models of pancreatic
cancer (Journal of the National Cancer Institute, Vol. 99, Issue 2,
January 17 2007, 105-107). The Company, in exchange for 550,000
restricted shares of its common stock, was assigned all the rights
in the U.S. and in foreign countries to the applications for these
inhibitors developed at Johns Hopkins University by their inventors
Drs. Saeed Khan, Gurulingappa Hallur, Manuel Hidalgo and Antonio
Jimeno. This acquisition is the Company's initial step in building
a biotechnology company from the ground up with a future portfolio
of possible therapeutic drug candidates among other ventures that
it is actively exploring. The Company plans to develop candidates
from its portfolio of therapeutic compounds and partner with
pharmaceutical and/or biotechnology partners for development,
regulatory approval and marketing as appropriate. This press
release contains "forward-looking statements" (within the meaning
of the Private Securities Litigation Act of 1995) that inherently
involve risk and uncertainties. The Company generally uses words
such as "believe," "may," "could," "will," "intend," "expect,"
"anticipate," "plan," and similar expressions to identify
forward-looking statements. One should not place undue reliance on
these forward-looking statements. The Company's actual results
could differ materially from those anticipated in the
forward-looking statements for many unforeseen factors, which may
include, but are not limited to, changes in general economic
conditions, the ongoing threat of terrorism, ability to have access
to financing sources on reasonable terms and other risks that are
described in this document. Although the Company believes the
expectations reflected in the forward-looking statements are
reasonable, they relate only to events as of the date on which the
statements are made, and the Company's future results, levels of
activity, performance or achievements may not meet these
expectations. The Company does not intend to update any of the
forward-looking statements after the date of this press release to
conform these statements to actual results or to changes in the
Company's expectations, except as required by law. DATASOURCE:
Champions Biotechnology, Inc. CONTACT: James Martell of Champions
Biotechnology, Inc., +1-703-526-0400
Copyright